Novocure
NVCR
14.66
-0.31
-2.07%
Novocure
US · NVCR
#2889 by market cap
Listed 2015
14.66
-0.31
-2.07%
Live - 5344 symbols - heartbeat 464s ago
· 2026-10-08 07:25
Pre-market
14.66
-0.01%
After-hours
14.66
0.00%
Overnight
14.65
-0.07%
- Market cap
- 1.71B
- P/E (TTM)i
- -11.28
- P/Bi
- 5.05
- EPSi
- -1.22
- Div yieldi
- 0.00%
- 52W posi
- 42%
Reader sentiment
Are you bullish or bearish on NVCR?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is 0.78, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +8.28% YoY
Margins
- Gross margin
- 74.54%
- Operating margin
- -23.47%
- Net margin
- -20.79%
Key ratios & quality
- Enterprise valuei
- 1.47B
- Altman Z-Scorei
- 0.78
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 248.07M | 351.32M | 494.37M | 535.03M | 537.84M | 509.34M | 605.22M | 655.35M |
| Gross profit | 168.02M | 262.71M | 387.87M | 420.15M | 422.97M | 381.06M | 468.04M | 488.47M |
| Selling & admin expenses | 151.12M | 184.62M | 225.45M | 263.18M | 306.41M | 390.87M | 428.89M | 417.73M |
| Research & development | 50.57M | 79.00M | 132.01M | 201.30M | 206.09M | 223.06M | 209.65M | 224.54M |
| Operating profit | -33.67M | -914.00K | 30.40M | -44.33M | -89.52M | -232.87M | -170.50M | -153.80M |
| Pretax profit | -45.94M | -8.82M | 18.10M | -52.08M | -81.85M | -191.74M | -131.16M | -136.25M |
| Tax | 17.62M | -1.59M | -1.71M | 6.28M | 10.69M | 15.30M | 37.47M | -23.00K |
| Net profit | -63.56M | -7.23M | 19.81M | -58.35M | -92.53M | -207.04M | -168.63M | -136.23M |
| Basic EPS | -1 | 0 | 0 | -1 | -1 | -2 | -2 | -1 |
| Diluted EPS | -0.69 | -0.07 | 0.18 | -0.56 | -0.88 | -1.95 | -1.56 | -1.22 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 154.99M | 158.81M | 167.20M | 174.35M | 174.06M | 183.58M |
| Gross profit | 116.47M | 117.33M | 122.48M | 132.19M | 135.13M | 142.48M |
| Selling & admin expenses | 100.56M | 101.02M | 104.47M | 111.68M | 144.21M | 101.59M |
| Research & development | 53.78M | 55.83M | 54.03M | 60.91M | 58.34M | 51.45M |
| Operating profit | -37.87M | -39.52M | -36.02M | -40.39M | -67.42M | -10.56M |
| Pretax profit | -30.30M | -34.98M | -30.02M | -40.95M | -69.26M | -12.45M |
| Tax | 4.02M | 5.16M | 7.25M | -16.46M | 1.88M | 3.21M |
| Net profit | -34.32M | -40.14M | -37.27M | -24.50M | -71.14M | -15.66M |
| Basic EPS | 0 | 0 | 0 | 0 | -1 | 0 |
| Diluted EPS | -0.31 | -0.36 | -0.33 | -0.22 | -0.62 | -0.13 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 321.37M | 439.95M | 999.44M | 1.07B | 1.11B | 1.03B | 1.11B | 646.73M |
| Cash & ST investments | 245.88M | 326.09M | 842.58M | 937.70M | 969.43M | 910.62M | 959.87M | 447.67M |
| Inventory | 22.56M | 23.70M | 27.42M | 24.43M | 29.38M | 38.15M | 35.09M | 41.11M |
| Total assets | 339.79M | 479.45M | 1.05B | 1.14B | 1.19B | 1.15B | 1.24B | 804.33M |
| Total current liabilities | 64.56M | 86.31M | 113.61M | 142.60M | 158.78M | 179.12M | 756.39M | 223.23M |
| Short-term debt | -- | -- | -- | -- | -- | 8.32M | 566.07M | 11.66M |
| Long-term debt | 149.27M | 149.42M | 429.91M | 562.22M | 565.51M | 568.82M | 97.30M | 195.05M |
| Total liabilities | 227,534,000.00 | 261,658,000.00 | 575,457,000.00 | 729,001,000.00 | 750,478,000.00 | 783,633,000.00 | 880,605,000.00 | 463,860,000.00 |
| Total equity | 112.26M | 217.79M | 476.53M | 410.49M | 441.17M | 362.50M | 360.18M | 340.47M |
| Retained earnings | -643.66M | -650.89M | -631.08M | -685.93M | -778.46M | -985.50M | -1.15B | -1.29B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 1.09B | 1.08B | 1.20B | 646.73M | 631.66M | 638.52M |
| Cash & ST investments | 929.13M | 911.53M | 1.03B | 447.67M | 432.00M | 440.56M |
| Inventory | 39.47M | 40.21M | 39.10M | 41.11M | 43.46M | 42.22M |
| Total assets | 1.25B | 1.25B | 1.36B | 804.33M | 787.93M | 795.19M |
| Total current liabilities | 743.31M | 749.63M | 776.01M | 223.23M | 217.58M | 220.71M |
| Short-term debt | 558.97M | 559.79M | 560.62M | 11.66M | -- | -- |
| Long-term debt | 97.45M | 97.61M | 194.64M | 195.05M | 195.46M | 195.89M |
| Total liabilities | 886,851,000.00 | 896,434,000.00 | 1,019,861,000.00 | 463,860,000.00 | 457,209,000.00 | 457,099,000.00 |
| Total equity | 361.96M | 349.44M | 341.33M | 340.47M | 330.72M | 338.09M |
| Retained earnings | -1.19B | -1.23B | -1.27B | -1.29B | -1.36B | -1.38B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -1.87M | 26.62M | 99.15M | 82.76M | 30.79M | -73.34M | -26.37M | -49.03M |
| Depreciation & amortization | 9.01M | 8.46M | 9.15M | 10.25M | 10.62M | 10.97M | 11.24M | 14.65M |
| Free cash flow | -8.58M | 16.14M | 84.18M | 58.59M | 9.43M | -100.43M | -69.22M | -75.68M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 1.84M | 2.47M | 3.37M | 4.55M | 5.22M | 4.42M | 4.15M | 3.66M |
| Ending cash balance | 142.76M | 179.42M | 246.17M | 209.61M | 115.83M | 242.56M | 166.09M | 103.39M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -35.67M | -15.94M | 20.57M | -18.00M | -13.52M | 8.13M |
| Depreciation & amortization | 3.33M | 3.44M | 3.66M | 4.22M | 4.12M | 4.31M |
| Free cash flow | -46.28M | -21.42M | 14.92M | -22.90M | -18.67M | 1.22M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 2.14M | 0 | 1.52M | 0 | 2.09M |
| Ending cash balance | 129.43M | 152.13M | 344.64M | 103.39M | 97.32M | 103.62M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -56.29 | -4.38 | 5.71 | -13.16 | -21.73 | -51.52 | -46.67 | -38.89 |
| ROA %i | -21.01 | -1.77 | 2.59 | -5.33 | -7.94 | -17.71 | -14.13 | -13.32 |
| ROIC %i | -23.53 | 0.12 | 4.82 | -5.92 | -9.80 | -22.17 | -13.89 | -16.18 |
| 5-year avg ROE %i | -59.08 | -47.99 | -34.05 | -23.26 | -17.97 | -17.02 | -25.47 | -34.39 |
| EBIT margin %i | -13.08 | 1.39 | 7.23 | -9.09 | -14.60 | -36.99 | -19.96 | -18.19 |
| FCF / sales %i | -- | 4.59 | 17.03 | 10.95 | 1.75 | -- | -- | -- |
| Current ratioi | 4.98 | 5.10 | 8.80 | 7.53 | 7.00 | 5.78 | 1.46 | 2.90 |
| Quick ratioi | 4.54 | 4.77 | 8.42 | 7.32 | 6.77 | 5.51 | 1.40 | 2.63 |
| Debt / assetsi | 43.93 | 34.12 | 42.22 | 50.48 | 49.03 | 52.75 | 55.07 | 30.88 |
| LT debt / equityi | 132.97 | 75.10 | 93.22 | 140.13 | 132.44 | 164.48 | 32.56 | 69.52 |
| Interest coveragei | -2.41 | 0.36 | 2.02 | -14.14 | -23.55 | -56.77 | -11.68 | -7.00 |
| Revenue CAGR (3Y) %i | 95.72 | 61.83 | 40.82 | 29.20 | 15.25 | 1.00 | 4.19 | 6.81 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -16.39 | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -45.52 | -48.07 | -50.60 | -38.89 | -49.96 | -43.22 |
| ROA %i | -13.85 | -13.91 | -13.75 | -13.32 | -16.99 | -14.56 |
| ROIC %i | -12.77 | -12.92 | -16.33 | -16.18 | -32.49 | -27.99 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -18.85 | -19.54 | -19.78 | -18.19 | -22.06 | -17.14 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 1.47 | 1.45 | 1.55 | 2.90 | 2.90 | 2.89 |
| Quick ratioi | 1.41 | 1.39 | 1.49 | 2.63 | 2.66 | 2.66 |
| Debt / assetsi | 55.79 | 56.21 | 58.62 | 30.88 | 29.82 | 29.35 |
| LT debt / equityi | 38.06 | 40.20 | 69.53 | 69.52 | 71.04 | 69.04 |
| Interest coveragei | -- | -- | -- | -7.00 | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Development, manufacture and commercialization of Tumor Treating Fields (TTFields) as treatment for100.00%
Region
United States58.84%
Germany12.12%
France11.63%
Other international markets8.68%
Japan5.77%
Greater China2.97%
Quote time 2026-10-08 07:25:40 · For reference only, not investment advice and not tailored to your situation.